


wherein n is 0 or 1, and R is selected from the group consisting of C<sub>1-10</sub> alkyl, C<sub>6-10</sub> aryl  
and



and wherein when n is 0, R is not C<sub>6-10</sub>.

16. (Amended) A composition, which composition comprises the compound of claim 1, or a pharmaceutically acceptable salt thereof, and an anti-*H. pylori* agent.

17. (Amended) The composition of claim 16, wherein the anti-*H. pylori* agent is PPI, metronidazole, clarithromycin or amoxicillin.

b2  
18. (Amended) A method for treating or preventing a disease or disorder caused by *H. pylori* infection, which method comprises administering, to a subject to which such treatment or prevention is needed or desirable, an effective amount of the composition of claim 16, or a pharmaceutically acceptable salt thereof, thereby said disease or disorder is treated or prevented.

b3  
20. (Amended) A kit, which kit comprises the composition of claim 16, and an instruction for using said composition in treating or preventing a disease or disorder caused by *H. pylori* infection.

Please add new claim 21 as follows.

b4  
21. (New) A pharmaceutical composition, which composition comprises the compound of claim 2.

#### REMARKS

Upon entry of the present Amendment, claims 1-21 will be pending. As agreed upon in a teleconference between the Examiner and the undersigned today, the amendments of claims 1, 16-18 and 20 place the pending claims into form of allowance. Support for new claim 21 can be


found throughout the specification and, *inter alia*, in claims 1-3 as originally filed. Therefore, the above-described amendments do not introduce any new matter into the present application.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. **524022000100**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: December 26, 2002

By:


  
Peng Chen  
Registration No. 43,543

Morrison & Foerster LLP  
3811 Valley Centre Drive, # 500  
San Diego, CA 92130-2332  
Telephone: (858) 720-5117  
Facsimile: (858) 720-5125

**EXHIBIT A. VERSION WITH MARKINGS TO SHOW CHANGES MADE**

Please amend claims 1, 16-18 and 20 as follows:

1. (Twice Amended) A compound, or a pharmaceutically acceptable salt thereof, having the following formula I:



wherein n is 0 or 1, and R is selected from the group consisting of C<sub>1-10</sub> alkyl, [C<sub>1-10</sub>] C<sub>6-10</sub> aryl and



and wherein when n is 0, R is not [C<sub>1-10</sub>] C<sub>6-10</sub>.

16. (Amended) A [combination] composition, which [combination] composition comprises the compound of claim 1, or a pharmaceutically acceptable salt thereof, and an anti-*H. pylori* agent.


17. (Amended) The [combination] composition of claim 16, wherein the anti-*H. pylori* agent is PPI, metronidazole, clarithromycin or amoxicillin.

18. (Amended) A method for treating or preventing a disease or disorder caused by *H. pylori* infection, which method comprises administering, to a subject to which such treatment or prevention is needed or desirable, an effective amount of the [combination] composition of claim 16, or a pharmaceutically acceptable salt thereof, thereby said disease or disorder is treated or prevented.

20. (Amended) A kit, which kit comprises the [combination] composition of claim [15] 16, and an instruction for using said [combination] composition in treating or preventing a disease or disorder caused by *H. pylori* infection.

**EXHIBIT B. ALL PENDING CLAIMS**

1. (Twice Amended) A compound, or a pharmaceutically acceptable salt thereof, having the following formula I:




wherein n is 0 or 1, and R is selected from the group consisting of C<sub>1-10</sub> alkyl, C<sub>6-10</sub> aryl and



and wherein when n is 0, R is not C<sub>6-10</sub>.

2. The compound of claim 1, which has the following formula II:



3. A pharmaceutical composition, which composition comprises the compound of claim 1.
4. The pharmaceutical composition of claim 3, which further comprises a pharmaceutically acceptable carrier or excipient.
5. A method for treating or preventing a disease or disorder caused by *Helicobacter pylori* (*H. pylori*) infection, which method comprises administering, to a subject to which such treatment or prevention is needed or desirable, an effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof, thereby said disease or disorder is treated or prevented.

6. The method of claim 5, wherein the subject is a mammal.
7. The method of claim 6, wherein the mammal is a human.
8. The method of claim 5, which comprises administering the compound of claim 2, or a pharmaceutically acceptable salt thereof, to the subject.
9. The method of claim 5, which comprises administering the pharmaceutical composition of claim 3 to the subject.
10. The method of claim 5, wherein the disease or disorder caused by *H. pylori* infection to treated or prevented is chronic gastritis, gastroduodenal ulcer, adenocarcinoma of the distal stomach, gastric lymphoma or gastric cancer.
11. The method of claim 5, wherein the subject is treated without administering an anti-*H. pylori* agent.
12. The method of claim 11, wherein the anti-*H. pylori* agent is proton-pump inhibitor (PPI), metronidazole, clarithromycin or amoxicillin.
13. The method of claim 5, wherein the *H. pylori* is a resistant strain induced by PPI, metronidazole, clarithromycin or amoxicillin treatment.
14. The method of claim 5, wherein the compound or a pharmaceutically acceptable salt thereof is administered by intracavernous injection, subcutaneous injection, intravenous injection, intramuscular injection, intradermal injection, oral administration, or topical administration.
15. (Amended) The method of claim 5, which further comprises a step of diagnosis or prognosis of *H. pylori* infection in the subject.

16. (Amended) A composition, which composition comprises the compound of claim 1, or a pharmaceutically acceptable salt thereof, and an anti-*H. pylori* agent.

17. (Amended) The composition of claim 16, wherein the anti-*H. pylori* agent is PPI, metronidazole, clarithromycin or amoxicillin.

18. (Amended) A method for treating or preventing a disease or disorder caused by *H. pylori* infection, which method comprises administering, to a subject to which such treatment or prevention is needed or desirable, an effective amount of the composition of claim 16, or a pharmaceutically acceptable salt thereof, thereby said disease or disorder is treated or prevented.

19. A kit, which kit comprises the compound of claim 1, or a pharmaceutically acceptable salt thereof, and an instruction for using said compound or pharmaceutically acceptable salt in treating or preventing a disease or disorder caused by *H. pylori* infection.

20. (Amended) A kit, which kit comprises the composition of claim 16, and an instruction for using said composition in treating or preventing a disease or disorder caused by *H. pylori* infection.

21. (New) A pharmaceutical composition, which composition comprises the compound of claim 2.